Monopar Therapeutics to Present at Upcoming Investor Conferences

Rhea-AI Summary

Monopar Therapeutics Inc. (Nasdaq: MNPR), a biopharmaceutical company focused on cancer therapeutics, announced upcoming presentations by CEO Chandler D. Robinson at several investor conferences in March. The presentations include:

• H.C. Wainwright Global Life Sciences Conference on March 9, 2021, at 7:00 a.m. ET.
• 33rd Annual Roth Conference on March 16, 2021, at 12:00 p.m. ET.
• Maxim’s 2021 Emerging Growth Virtual Conference on March 17, 2021, with the timing to be determined.

Monopar develops therapeutics aimed at improving cancer patients' lives.

WILMETTE, Ill., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced that Chandler D. Robinson, MD, Chief Executive Officer, is planning to present a Company overview at the following investor conferences in March:

H.C. Wainwright Global Life Sciences Conference
The Company’s presentation will be webcast on Tuesday, March 9, 2021 at 7:00 a.m. ET

33rd Annual Roth Conference, Healthcare
The Company’s fireside chat will be webcast on Tuesday, March 16, 2021 at 12:00 p.m. ET

Maxim’s 2021 Emerging Growth Virtual Conference
Presentation time to be determined on Wednesday, March 17, 2021

About Monopar Therapeutics Inc.
Monopar Therapeutics is a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar’s pipeline consists of Validive® for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin for the treatment of advanced soft tissue sarcoma; and a late-stage preclinical antibody, MNPR-101, for advanced cancers and severe COVID-19. For more information, visit: www.monopartx.com.

CONTACT:

Monopar Therapeutics Inc:
Investor Relations
Kim R. Tsuchimoto
Chief Financial Officer
kimtsu@monopartx.com

Follow Monopar on social media for updates:

Twitter: @MonoparTx    LinkedIn: Monopar Therapeutics

FAQ

What are the upcoming investor conferences where Monopar Therapeutics (MNPR) will present?

Monopar Therapeutics will present at the following: H.C. Wainwright Global Life Sciences Conference on March 9, 2021, at 7:00 a.m. ET; 33rd Annual Roth Conference on March 16, 2021, at 12:00 p.m. ET; and Maxim’s 2021 Emerging Growth Virtual Conference on March 17, 2021.

Who is presenting for Monopar Therapeutics at the investor conferences?

Chandler D. Robinson, MD, the Chief Executive Officer, will present for Monopar Therapeutics (MNPR) at the upcoming investor conferences.

What is the focus of Monopar Therapeutics (MNPR)?

Monopar Therapeutics focuses on developing therapeutics designed to extend life and improve the quality of life for cancer patients.

When is the H.C. Wainwright Global Life Sciences Conference presentation for MNPR?

The H.C. Wainwright Global Life Sciences Conference presentation for Monopar Therapeutics (MNPR) is scheduled for March 9, 2021, at 7:00 a.m. ET.

What is the significance of the presentations for Monopar Therapeutics (MNPR)?

The presentations at these investor conferences provide Monopar Therapeutics (MNPR) an opportunity to share their advancements in developing cancer therapeutics and engage with potential investors.